What we do Viyash Scientific Ltd is a global pharmaceutical company specializing in Animal Health formulations, APIs, and analytical services, focused on innovation and market expansion across multiple continents. |
Founded in 2,003 |
Market share Strong presence in Europe, Asia, and emerging markets with diversified product portfolio and growing market share in animal health sectors. |
Problem solved Provides affordable, high-quality animal health solutions addressing veterinary pharma needs globally with a focus on formulations, APIs, and services. |
Top clients or who we serve Serves farm and companion animal health sectors globally with B2B model; major clients include distributors and veterinary companies in Europe, USA, Asia, and emerging markets. |
Key management Dr. Kamal Sharma (Chairman), Mr. Rajaram Narayanan (Managing Director & CEO), Mr. Vedprakash Ragate (Whole-time Director). |
Our journey and innovations Amalgamation in 2003; expanded global footprint through acquisitions; established multiple manufacturing plants; enhanced R&D capabilities with over 200 team members and advanced labs. |
Where we operate Europe, Asia, Americas, Middle East, and emerging markets including India, Brazil, Mexico, Turkey, USA, and Japan. |
Top products or what we offer Animal health formulations, advanced APIs, injectable products, and analytical services with multiple global regulatory approvals and a growing product pipeline. |
Top brands Phyto-solutions bio-actives, Tulaject injectable (Tuathromycin based), strong presence in anesthetics and complex generics markets. |
Raw materials needed Active pharmaceutical ingredients, essential oils for nutritional bio-actives, advanced intermediates, and specialized chemical compounds for formulations. |
Raw materials supplier Suppliers vary by region; strategic backward integration efforts to optimize costs and supply reliability. |
Recurring vs cyclical contribution Revenue primarily recurring from pharmaceuticals and analytical services with steady growth from new product introductions and expanding markets. |
Our industry position Leading animal health pharma company with EUGMP-approved manufacturing, recognized safety and quality certifications, and growing footprint in global markets. |
Financial highlights Consolidated revenue ₹15,513.7 Mn (FY 24-25), net profit ₹322.59 Mn; standalone revenue ₹1,782.57 Mn, net profit ₹157.94 Mn; consistent EBITDA growth and improved margins. |
Geographical revenue split Revenue from Europe ₹700.2 Mn, Asia ₹444.95 Mn, Rest of World ₹406.23 Mn as per recent disclosures. |
Order book - |
Whats driving growth New product launches, regulatory approvals, geographic expansion, cost competitiveness, and enhanced R&D capabilities. |
Our future plans Advancing synergy realization post-merger, expanding R&D pipelines, increasing production capacity, and exploring new business segments and geographies. |
Our green promise - |
Our people and values Employs a skilled workforce with over 250 R&D members; emphasizes safety, ethics, and diversity across global operations. |
Key challenges ahead Navigating regulatory approvals, competitive pressures in generics and animal health, supply chain optimization, and integration of subsidiaries. |
Interesting facts First merged entity financial results showed strong margin expansion and debt reduction; Vizag site awarded CII Safety Leadership Gold. |
Risks and strategy Risks include regulatory compliance and market competition; mitigation via robust R&D, cost optimization, and diversified global presence. |
